Incidence rate of SARS-CoV-2 infection, risk factors, and safety after BBIBP-CorV COVID-19 vaccine in adolescent in Thailand.

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210920006

Enrollment

50000

Registered

2021-09-20

Start date

2021-09-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incident rate, risk factor of infection, and safety profile after complete of 2 dose of the BBIBP-CorV COVID-19 vaccine in adolescent in Thai population. COVID-19 vaccine, Sinopharm, adolescent, safety, incident rate, risk factors.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

10 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. age 10-18 year old 2. no active underlying disease. 3. informed to participated the study.

Exclusion criteria

Exclusion criteria: 1. previous infection with SAR-CoV-2 2. previous received SAR-CoV-2 vaccine 3. receive any vaccine with 14 days 4. Fever at vaccination day 5. History of URI within 14 days 6. History of seizure. 7. Abnormal development 8. Pregnancy. 9. Lactation. 10. History of severe allergy to vaccine.

Design outcomes

Primary

Measure	Time frame
Incident rate of COVID-19 after complete of BBIBP-CorV for 2 week s 2 week after complete of 2 dose of vaccine new case of COVID-19 in study period	—

Secondary

Measure	Time frame
Risk factor of COVID-19 in adolescents after complete of 2 dose of BBIBP-CorV vaccine 2 week after complete of 2 dose of vaccine Multivaliate analysis,Safety profile after vaccination. at day1, day7, and day30 after vaccination Questionnaire after vaccination	—

Countries

Thailand

Contacts

Public ContactKriangkrai Tawinprai

HRH Princess Chulabhorn College of Medical Science

Kriangkrai.taw@pccms.ac.th02576 6000

Outcome results